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LYSINE ACETYLTRANSFERASE 5 IN EGFR MUTATED NON-SMALL CELL 
LUNG CANCER 
GILBERT PAN 
ABSTRACT 
 Histone modifications are crucial in activities such as transcriptional activation, 
gene silencing, and epigenetic cellular memory. In particular, lysine acetylation via lysine 
(K) acetyltransferases (KATs) has been implicated in cancer development. Interestingly, 
KAT5, also known as Tip60 (tat-interactive protein-60kDa), has been reported to possess 
both tumor promoting and tumor suppressing properties depending on the context of 
malignancy. Herein we report that KAT5 contributes to tumorigenesis in epidermal 
growth factor receptor (EGFR) mutated lung cancer, and Kat5-knockout mice models 
demonstrate significantly reduced lung tumor burden. To probe the aberrant modification 
of KAT5, we demonstrated that KAT5 binds to and is phosphorylated by oncogenic 
EGFR in co-immunoprecipitation experiments. Next, to investigate whether KAT5 is 
involved in cell proliferation and survival, H1975 cells harboring L858R-T790M double-
activating mutations were transfected with doxycycline inducible short helical RNA 
(shRNA) targeting KAT5 (shKAT5). Following treatment, shKAT5 cells were observed 
to have suppressed proliferation rates. Pharmacological inhibition using TH1834, a 
known KAT5 inhibitor, also suppressed proliferation rates in shKAT5 cells; in contrast 
BEAS2B cells, an immortalized normal human bronchial cell line, surprisingly exhibited 
increased viability compared to transformed human lung H1975 cells. This finding 
supports KAT5’s context-dependent role in in normal and abnormal cell homeostasis. To 
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further investigate KAT5 in lung tumorigenesis in vivo, we generated EGFR-mutant 
conditional Kat5 knockout mice using a tetracycline-induced Cre/loxP system. Following 
doxycycline treatment for 10 weeks, isolated mice lungs for EGFRTL/CCSP-
rtTA/Cre/Kat5F/F possessed significantly lower tumor volume compared to 
EGFRTL/CCSP-rtTA/Cre/Kat5wt/F and EGFRTL/CCSP-rtTA/Cre/Kat5wt/wt mice lungs. 
Hemotoxylin and eosin staining showed no evident hyperproliferation in lungs isolated 
from EGFRTL/CCSP-rtTA/Cre/Kat5F/F mice whereas lungs isolated from EGFRTL/CCSP-
rtTA/Cre/Kat5wt/wt and EGFRTL/CCSP-rtTA/Cre/Kat5wt/F did, signifying that KAT5 has a 
potential regulatory role in cellular proliferation. RNA-Seq analysis of shKAT5 H1975 
cells identified downstream targets involved in tumorigenic pathways. Subsequent 
quantitative polymerase chain reaction (PCR) of shKAT5 cells served to validate the 
reported targets. Taken together, these data offer insight into a KAT5 mediated oncogenic 
pathway that can provide novel therapeutic approaches in treating lung cancer. 
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INTRODUCTION 
 This thesis serves to identify and assess the oncogenic role of lysine 
acetyltransferase 5 (KAT5), also known as tat-interactive protein-60KDA (Tip60), in 
lung tumorigenesis. The two predominant types of lung cancer are non-small cell lung 
cancer (NSCLC), which represents 85-90% of all reported cases, and small cell lung 
cancer (SCLC), which characterizes the remaining cases. The following introduction 
examines the social and clinical relevance of lung cancer in the context of epidermal 
growth factor receptor (EGFR) and KAT5 mutations.  
Lung Cancer in Society and Clinics 
 Lung cancer is the most common cause of cancer related deaths worldwide. Even 
with the latest drugs in development, lung cancer still possesses a dismal 18% 5-year 
survival rate as a terminal illness at all stages of disease1. Currently, optimal treatment for 
tumors confined to the lung is surgical resection at early stages; however, patients with 
locally advanced or metastatic disease are not ideal candidates for surgery and necessitate 
other treatment. The current standard protocol for non-operable metastatic lung cancer is 
a combination of platinum-based chemotherapy and thoracic radiation, which only 
provides limited patient survivability2. Recent advances in genomic testing and 
development of targeted therapies have moved the odds for curing thoracic malignancies 
forward, but much work remains to be done3.  
Targetable Mutations in Cancer 
The identification of targetable mutations in non-small cell lung cancer has 
provided individualized therapies to inhibit oncogenic signaling pathways. EGFR 
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mutations are one of most prolific in NSCLC, accounting for more than 60% of cases4. 
EGFR functions as a trans-membrane protein critical to intracellular signaling pathways. 
The receptor binds to activating ligands which leads to homo- or heterodimerization with 
HER2 and subsequent trans-phosphorylation of tyrosine residues that contribute in 
downstream signaling pathways for cellular proliferation, invasion, and angiogenesis5. 
The development of tyrosine kinase inhibitors (TKIs) has led to higher objective response 
rates (ORRs) and progression-free survival (PFS) compared to traditional cytotoxic 
therapies in patients with identifiable EGFR mutations6. However, acquired resistances 
from further genomic alterations such as the T790M point mutation in EGFR have 
reduced or halted therapeutic efficacy, leading to the need to characterize the underlying 
mechanisms for lung cancer development and progression in order to introduce novel 
therapeutic targets7.  
Lysine Acetyltransferases in Cancer 
Aberrant epigenetic modifications in oncogenesis have long been an area of 
interest in cancer research. Lysine acetylation, a form of histone modification, has been 
associated with activating transcriptional processes in eukaryotic organisms. Acetylation 
on histones is catalyzed by proteins called histone acetyltransferases (HATs), which 
include a sub-type of enzymes known as lysine acetyltransferases (KATs)8. The three 
major acetyltransferase families are divided based on their protein sequence similarities: 
(1) GNAT (GCN5-related N-acetyltransferase), (2) MYST (Moz, Ybf2/Sas3, Sas2, and 
Tip60), and (3) CBP/p300 (CREB-binding protein/E1A binding protein p300)9. 
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Acetylation unfolds heterochromatin to euchromatin by neutralizing the basic charge of 
lysine, rendering the nucleosome transcriptionally accessible and active.  
KATs are subdivided based on the sequence of their catalytic domains. KAT5 is a 
founding member of the MYST family whose members function in chromatin 
remodeling, gene regulation, dosage compensation, DNA damage repair, and 
tumorigenesis10. KAT5 is a subunit in the NuA4 complex, which is recruited to target 
promoters by many transcription factors. However, KAT5 function in cancer 
development is complicated. Within the NuA4 complex, KAT5 acetylates nucleosomal 
histones H2A and H4 in addition to acting as a co-activator for transcriptional factors 
such as c-Myc and E2F11. In this context, KAT5 acts as a tumor initiator/promoter. 
However, KAT5 is also noted in p53 activation, commonly attributed to the induction of 
apoptosis12. Furthermore, KAT5 is required for the expression of KAI1, a tumor 
suppressor in the context of prostate cancer13. These context dependent roles of KAT5 
suggest complex regulatory properties that can either promote or suppress tumorigenesis 
in cancer. This current study identifies KAT5 as a required component for malignant 
transformation in pulmonary epithelial cells and develops a preliminary understanding of 
the underlying mechanism in lung tumorigenesis. 
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METHODS 
 
Mice 
The experimental studies were approved by the Institutional Animal Care and Use 
Committee at Beth Israel Deaconess Medical Center. Kat5 conditional knockout mice for 
lung tumor analysis (Kat5F/F) were generated by crossing lung-specific EGFR-L858R-
T790M (EGFRTL) transgenic mice with conditional Kat5 tetracycline-inducible Cre-
expressing mice (TetOp-Cre/Kat5F/F) that targets pulmonary cells via clara cell secreting 
protein (CCSP) using a reverse tetracycline-controlled transactivator (rtTA) system. To 
induce Kat5 EGFRTL expression and excise Kat5, mice were fed a doxycycline diet for 8-
12 weeks (Envigo).  
Cell Culture 
A431, A549, BEAS2B, NCI-H1395, NCI-H1975, NCI-H3132, NCI-H358, HCC827, 
HCC98, and PC9 cells were grown at 37 ºC in a humidified incubator at 5% CO2 in 
RPMI (Corning) media supplemented with 10% fetal bovine serum (Corning), 100 µg/ml 
penicillin and 100 units/ml streptomycin (Corning).  
Generation of shKAT5 Cells  
TRIPZ inducible Lentiviral KAT5 shRNA plasmids (Dharmacon) were used to generate 
retroviruses by transfection into HEK293T cells using the TransIT-X2 Dynamic Delivery 
System (Mirus).  Retroviruses were then transduced into NCI-H1975 cells followed by 
puromycin selection (2.0 µg/ml) in Roswell Park Memorial Institute (RPMI) complete 
medium. Puromycin selection produced H1975 sh328, which harbors shRNA targeting 
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luciferase as a control. H1975 shKAT5 cell lines were generated using plasmids targeting 
different flanking regions of KAT5. To obtain KAT5 knockdown models, H1975 cells 
were cultured in the presence of doxycycline (1.0-2.0 µg/ml). KAT5 levels which were 
verified by quantitative PCR. Plasmid constructs can be found in Table 2.  
Cellular Proliferation Assay  
Cells ( ) were seeded in 24-well plates in RPMI complete medium. The following 
day, cells were treated with doxycycline (2.0µg/ml) to induce shRNA over the course of 
120 hours or were treated with TH1834. Cells were counted at 24, 72, and 120 hour 
marks. Media was changed every 48 hours. The CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega) containing 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) was used to assess  
cellular proliferation via a colorimetric method. The data was graphically displayed using 
GraphPad Prism (GraphPad Software).  
RNA-Sequencing 
RNA was isolated in triplicate from cells treated with doxycycline (0.5 µg/ml) after 48 
hours. Strand-specific RNA libraries were generated, and sequencing was performed 
using single-end reads (50 base pairs, average 20 million reads per sample) on the 
BGISEQ-500 platform (BGI). Expressed genes for shKAT5 were compared to controls 
with a posterior probability of equal expression (PPEE) of a fold change of >1.5.  
Quantitative PCR  
Total RNA was isolated from NCI-H1975 shKAT5 cells with the use of an RNA 
isolation kit (Qiagen, RNeasy Mini Kit). Up to 3 µg of RNA was reverse transcribed to 
1×103
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cDNA following the protocol of Invitrogen Superscript™ II Reverse Transcriptase 
protocol (ThermoFisher Scientific, Cat#18064014). ACTB and GAPDH expression levels 
were used to normalize for differences in RNA input. For all genes of interest, iTaq™ 
Universal SYBR® Green Supermix (BIO-RAD) was used for gene expression analysis. 
mRNA expression levels were quantified in technical triplicates with 150 ng cDNA in a 
15 µl reaction volume. Primers are shown in Table 1. Statistical significance was 
calculated with Student’s t-test.  
Table 1. Primers Used in Quantitative PCR for shKAT5 Knockdown Analysis 
Gene Primers 5' – 3' 
ACTB F AGTGTGACGTGGACATCCGCAA 
R ATCCACATCTGCTGGAAGGTGGAC 
KAT5 F AGGGAGTCAACGATCGCACGGGAGG 
R CACAGACAGGGAGTCTTAGCCAGGG 
MUC1 F GTGCCCCCTAGCAGTACCG 
R GACGTGCCCCTACAAGTTGG 
TGFB1 F AAGGACCTCGGCTGGAAGTG 
R CCCGGGTTATGCTGGTTGTA 
TGM2 F CTGGGCCACTTCATTTTGC 
R ACTCCTGCCGCTCCTCTTC 
 
Western Blotting and Immunoprecipitation 
Protein lysates were isolated from NCI-H1975 shKAT5 cells after treatment with 
doxycycline (2 µg/ml). Lysate total protein concentration was assessed by Bradford 
protein assay using spectrophotometry. For western blotting, lysates were separated on 
sodium dodecyl sulfate (SDS) polyacrylamide gels of varying percentages and transferred 
onto polyvinylidene difluoride membranes (Millipore) to be probed by antibodies for the 
protein of interest. 
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For immunoprecipitation studies, 1 mg of total cell lysate was mixed with antibodies for 
the protein of interest or with normal mouse IgG antibodies and incubated with protein G 
Sepharose beads (GE Health Care Life Sciences). The beads were precipitated by 
centrifugation, washed three times with phosphate buffered saline (PBS), and suspended 
in buffer solution.   
The antibodies used included those against: ß-actin (Santa Cruz, Cat#sc-47778); KAT5 
(Santa Cruz, Cat#sc-166323); EGFR (Cell Signaling Technology, Cat#2232); FLAG 
(Sigma-Aldrich, Cat#F3165); phosphor-EGFR (Fisher Scientific, Cat#44-788-G); goat 
anti-rabbit IgG, HRP conjugate (BIO-RAD, Cat#1706515); goat anti-mouse IgG, HRP 
conjugate (BIO-RAD, Cat#1706516).   
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RESULTS 
 
KAT5 Expression in Lung Cancer  
Decreased levels of KAT5 expression have been correlated with reduced 
tumorigenic activity in various cancers. KAT5 expression was examined in various non-
small cell lung cancer cell lines to assess its function in lung tumorigenesis. Western blot 
analysis showed all cell lines assessed expressed KAT5 (Fig. 1) including BEAS2B cells, 
which are an immortalized alveolar cell line. BEAS2B cells functioned as a control to 
assess basal KAT5 expression in non-tumorigenic cells compared to tumorigenic cells.  
 
Figure 1. Expression of KAT5 Protein in Human Lung Cancer Cell Lines 
KAT5 is expressed in lung cancer cell lines as well as an immortalized alveolar cell line, 
BEAS2B. α and β forms refer to two different splice variants of KAT5.  
Cellular Proliferation and KAT5 Inhibition 
NCI-H1975 cells harbor L858R-T790M double activating mutations in the EGFR 
gene that have been attributed to acquired drug-resistance in EGFR 1st - and 2nd –
generation tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer. To 
avoid confounding variables from clonal effects, two clones, sh331 and sh342, harboring 
inducible-shRNA targeting KAT5 were selected and subject to cellular proliferation 
analysis. Following doxycycline treatment to suppress KAT5 expression, shKAT5 cells 
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proliferated more slowly compared to cells expressing control luciferase-shRNA (sh328) 
over a 72-hour treatment course (Fig. 2). H1975 wild-type cells that were treated with 
TH1834 (Fig. 3), a known KAT5 inhibitor, demonstrated slower cellular growth in an 
MTS assay as well (Fig. 4). On the other hand, TH1834 treatment increased viability of 
BEAS2B cells, suggesting that KAT5 may function in suppressing proliferation of 
transformed cells, but not normal cells.  
 
Figure 2. Quantification of shKAT5 Cells Treated with Doxycycline (2.0 µg/ml) 
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KAT5 sh328 functions as a control with shRNA targeting luciferase. KAT5 sh331 and 
sh342 possess shRNA targeting KAT5 to genetically deplete KAT5 in H1975 cells. Cells 
were counted at day 1 (24 h), day 2 (48 h), and day 3 (72 h) via 3 random fields per well 
with a microscope at 10X magnification. * indicates p < 0.01. 
 
 
 
 
 
 
 
 
 
 
Figure 3. Histone Acetyltransferase Inhibitor TH1834 
  
 
Figure 4. Pharmacological KAT5 Inhibition Decreases Cell Viability 
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H1975 and BEAS2B cells were treated with TH1834 for 72-hours in 96-well plates (3000 
cells/well) and subject to an MTS assay.  
In Vivo Lung-Specific Kat5 Knockout Mice 
Juvenile mice (3-6 weeks of age) were subject to a doxycycline infused diet for 8-
15 weeks. Lungs were isolated, weighed, and histologically analyzed. Genetic deletion of 
Kat5 was validated by PCR-based genotyping. Lungs isolated from EGFRTL/CCSP-
rtTA/Cre/Kat5wt/wt and EGFRTL/CCS-rtTA/Cre/Kat5wt/F exhibited tumors 10 weeks after 
doxycycline treatment (Fig. 5). Histological analysis revealed tumor islets in the 
bronchial and alveolar space for Kat5wt/wt  (Fig. 6II) and Kat5wt/F (Fig. 6III) mice lungs. 
However, lungs collected from EGFRTL/CCSP-rtTA/Cre/Kat5F/F (Fig. 6IV) and CCSP-
rtTa/Cre/Kat5wt/wt (Fig. 6I) mice exhibited similar features and appeared normal with no 
signs of hyperproliferation or tumor formation. Examination of gross appearance showed 
no difference in tumor growth as well  (Fig. 7). Weight of mice right lungs supported the 
histological analysis and affirmed EGFRTL/CCSP-rtTA/Cre/Kat5wt/wt and EGFRTL/CCS-
rtTA/Cre/Kat5wt/F to have heavier lungs compared to EGFRTL/CCSP-rtTA/Cre/Kat5F/F 
and control CCSP-rtTa/Cre/Kat5wt/wt (Fig. 8). These results show complete excision of 
the Kat5 gene resulted in loss of Kat5 protein in oncogenic pulmonary cells reduced 
tumor burden. Importantly, it exposes a therapeutic opportunity by targeting KAT5 in 
EGFR mutated non-small cell lung cancer.  
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Figure 5. PCR-Based Genotyping Affirming Induced Genetic Variations in Mice 
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Figure 6. Kat5 Knockout Hinders Tumor Formation In Vivo 
Hemotoxylin and eosin staining of lungs from indicated mice (I) CCSP-rtTa/Cre/Kat5wt/wt 
(II) EGFRTL/CCSP-rtTA/Cre/Kat5wt/wt (III) EGFRTL/CCS-rtTA/Cre/Kat5wt/F (IV) 
EGFRTL/CCSP-rtTA/Cre/Kat5F/F  
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Figure 7. Gross Appearance of Right Lung of Mice 
 
Figure 8. Lung Weight from Doxycycline Treatment of Mice  
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Weight of right lungs isolated from mice was measured. * indicates p<0.01 while N.S. 
signifies no significance was detected.  
RNA-Sequencing  
Three distinct H1975 shKAT5 cells (sh328, sh331, and sh342) were subjected to 
transcriptome analysis and sequencing. H1975 sh328 cells harbored an shRNA targeting 
luciferase, which functioned as a control. H1975 sh331 and sh342 were selected from a 
pool of nine candidates (Table 2). The selected clones harbored shRNA targeting KAT5 
at different exons and exhibited optimal downregulation of KAT5 via quantitative PCR 
assessment. Gene ontology analysis provided a functional classification for genes of 
interest at a macro level (Fig. 9) by illustrating cellular processes correlated with a 
downregulation of KAT5. Raw RNA-sequencing data revealed 576 overlapped 
differential genes between sh331 and sh342 that possessed changes in gene expression of 
fold change greater than 1.5 compared to the control (Fig 10). Common genes associated 
with tumorigenesis and cell-cycle regulation such as MUC1, TGFB1, and TGM2 were 
identified and subject to mRNA analysis to confirm the fold change observed in RNA-
Seq.  
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Table 2. TRIPZ Lentiviral Vector Sequences 
TRIPZ Inducible Lentiviral Vectors 
sh329 CACAGACCCTTTCCTCTTCTAC 
sh330 TAACTCTTGTTCTTACGTC 
sh331 TTCCATCAGAGCTGTCCTG 
sh333 TGGGCTACTTCTCCAAGGAGAGAA 
sh342 CGATTTTCGCTTCCGTCCT 
sh343 TCATAGCTGAACTCGATCA 
sh344 TATGGTCAAGGAAACACTT 
sh345 TCACTAATCTCATTGATGG 
sh346 CGTAGGTCACACTTGGTCA 
 
 
Figure 9. GO Functional Classification for H1975 shKAT5 Cells 
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Gene ontology analysis of RNA-sequencing results for H1975 shKAT5 (sh331 and 
sh342) cells show multiple cellular processes were affected upon genetic depletion of 
KAT5.  
 
 
Figure 10. Venn Diagram Illustrating Overlapped Genes with 1.5 Fold Change or 
Greater  
HAT Activity Assay and Immunoprecipitation  
HEK239T cells were transfected with KAT5 and EGFR overexpression 
constructs to probe mutant EGFR activity in relation to KAT5 acetyltransferase activity. 
Cells co-transfected with both KAT5 and EGFR exhibited higher HAT activity compared 
to cells solely transfected with KAT5. HAT activity was observed to be the highest in 
cells transfected with KAT5 and mutant EGFR-L858R-T790M (Fig. 11). Addition of 
osimertinib, an EGFR tyrosine kinase inhibitor restored HAT activity for HEK293T cells 
transfected with KAT5 and mutant EGFR compared to wild-type HEK293T EGFR HAT 
levels.  
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Immunoprecipitation experiments showed KAT5 was tyrosine phosphorylated in 
HEK293T cells expressing KAT5 and EGFR constructs. The level of phosphorylation 
observed was higher in cells transfected with mutant EGFR-L858R-T790M than 
compared to cells transfected with wild-type EGFR, implying EGFR may be responsible 
for phosphorylating KAT5. EGF stimulation to cells co-transfected with wild-type EGFR 
enhanced KAT5 phosphorylation (Fig 12). Subsequently, afatinib, an EGFR tyrosine 
kinase inhibitor, was used to treat cells possessing EGFR and in cells possessing tyrosine-
kinase inactive form of mutant EGFR, EGFR-KD (Fig. 13). Additionally, it is of interest 
to note that ß-catenin was observed to bind to KAT5 cells transfected with mutant EGFR 
(Fig. 14).  
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Figure 11. Inhibition of EGFR Tyrosine Kinase Activity with Osimertinib Decreases 
KAT5 Acetyltransferase Activity 
HEK293T cells were transfected with a KAT5 expression construct plus either 
wild-type EGFR or mutant EGFR-L858R-T790M expression constructs. Nuclear extracts 
were subject to a colorimetric HAT activity assay.  
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Figure 12. EGF Stimulation Releases KAT5 Bound to EGFR 
A431 cells were serum-stared overnight and treated with 100 ng/ml EGF for 2 hours. Cell 
extracts were co-immunoprecipitated with anti-KAT5 antibody. WCE indicates whole 
cell extracts.  
	21 
 
Figure 13. Oncogenic EGFR Binds and Phosphorylates KAT5. * indicates heavy 
chain (ß form) of KAT5 
HEK293T cells were transfected with a KAT5 expression construct and either a mutant 
EGFR expression construct containing L858R and T790M mutations (EGFR-LR-TM) or 
an EGFR-KD construct. Extracts were immunoprecipitated with an anti-KAT5 antibody. 
* indicates heavy chain.  
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Fig 14. KAT5 Binds ß-catenin in cells expressing mutant EGFR 
HEK293T cells were co-transfected with KAT5 and ß-catenin expression constructs 
along with EGFR constructs. Extracts were immunoprecipitated using a MYC antibody.  
Quantitative PCR 
PCR targets were identified from RNA-Sequencing data that possessed a change of 
greater than 1.5 fold. Samples were assessed in technical triplicates and normalized to ß-
actin for relative comparison (Fig. 15).  
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Figure 15. Relative mRNA Quantities in H1975 shKAT5 With and Without 
Doxycycline Treatment 
Doxycycline treatment effectively reduces KAT5 by approximately 4-fold compared to 
untreated cells. * signifies a p < 0.05.  
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328-	 328+	 331-	 331+	 342-	 342+	A
ct
in
	%
	
shKAT5 TGFB1 
*	 *	
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DISCUSSION 
 
 The role of KAT5 in lung tumorigenesis is complex and at times, 
paradoxical. It is a multi-functional protein that affects a diverse variety of targets 
including transcriptional machinery, cell cycle regulators, and checkpoint inhibitors. The 
increase in viability observed in BEAS2B cells after HAT inhibitor treatment affirms the 
multi-faceted role KAT5 retains in lung tissue. The findings suggest KAT5 retains its 
tumor suppressive role in normal bronchial tissue; yet, in transformed cells, a novel 
oncogenic process may be occurring that characterizes the tumorigenic properties of 
KAT5.  
Our initial results demonstrate that KAT5 is involved in the development of lung 
tumors both in vitro and in vivo. The regulatory nature of KAT5 prompts the need to 
identify downstream genes and/or signals that may be responsible for lung tumorigenesis. 
KAT5 is known to be phosphorylated by a variety of different kinases such as CDC2, 
GSK3, cAbl, and p38α14–16.  However, relatively little is known about EGFR 
phosphorylating KAT5. The co-immunoprecipitatin of KAT5 and EGFR suggests that a 
protein complex may be forming. Further investigation is warranted to determine the role 
and properties of this complex.  
Previously, ß-catenin signaling had been shown to be required for EGFR induced 
lung cancer development where deletion of Ctnnb1 significantly inhibited tumor 
formation in mutant EGFR-driven lung cancer mouse models17. The binding between 
KAT5 and ß-catenin observed in immunoprecipitation (Fig 13) and association between 
KAT5 and EGFR suggests KAT5 may be involved in Wnt/ß-catenin signaling in mutant 
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EGFR lung cancer. Studies demonstrating KAT5 to be a coactivator of TCF-ß-catenin 
signaling further support an oncogenic EGFR pathway mediated by a KAT5-ß-catenin 
complex18. Our data indicates a structure is being formed between KAT5 and ß-catenin; 
whether that structure is directly responsible for tumorigenic consequences or influences 
downstream signaling remains to be elucidated.  
Lung-specific Kat5 knockout EGFR-L858R-T790M-induced lung cancer mice 
showed tumor formation to be nearly completely suppressed when mutant EGFR and 
Kat5 deletion were induced simultaneously. However, it is still unknown whether KAT5 
is required for tumor maintenance. Lung weight measured between EGFRTL/CCSP-
rtTA/Cre/Kat5wt/wt and EGFRTL/CCSP-rtTA/Cre/Kat5wt/F mice have no significant 
difference while there is a drastic reduction observed in EGFRTL/CCSP-rtTA/Cre/Kat5F/F. 
The complete knockout of Kat5 in mice demonstrated the only notable change in tumor 
volume compared to 50% Kat5 knockout mice (Fig. 6), which indicates there may exist a 
targetable therapeutic level of KAT5 for lung tumor treatment.  
At the same time, the significant changes derived from in vivo doxycycline-
induced models can be related to toxicity related to rtTa, Cre-recombinase, and 
doxycycline present in the mice19. Airspace enlargement without inflammation may 
occur in CCSP-rtTa mice20. Cre-recominbase has been attributed to G2/M cell cycle 
arrest, and the combination of Cre and doxycycline may contribute and enhance overall 
toxicity21. Still, these three reagents are essential for in vivo modeling of EGFR lung 
tumorigenesis and numerous controls have been implemented to ensure accurate data 
interpretation. Should toxicity concerns affect study groups, then bi-transgenic mice with 
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floxed Kat5 can be used to avoid chronic exposure to Cre-recombinase by administration 
of Cre-expressing recombinant adenoviruses22.  
HATs are generally recruited to target promoters by transcription factors23. 
Systematic identification of major effector genes downstream of KAT5 was conducted 
with RNA-Sequencing to assess the regulatory effect of KAT5 on relevant targets. 
Quantitative PCR assessment for KAT5 mRNA levels reveals a nearly 4-fold 
downregulation occurring using an inducible knockdown system for cell lines sh331 and 
sh342 (Fig. 15). Three potential targets, MUC1, TGFB1, and TGM2, demonstrated 
decreased mRNA expression levels following treatment, indicating the decrease in KAT5 
expression is correlative to these respective genes. MUC1 and TGM2 have been shown to 
mechanistically contribute to tumor growth via ß-catenin and EGFR pathways as well as 
inducing drug resistance, making these attractive targets for examining a relationship to 
KAT524–27. Similar to KAT5, the role of TGFB1 in cancer is complex and paradoxical, 
but its role in cancer is undeniable and warrants further investigation to clarify its specific 
role in relation to KAT5 and lung cancer28.  
A recent study confirmed the tumor suppressive properties of KAT5 in lung 
cancer models where elevated levels of KAT5 was attributed to tumor regression29. 
However, the cells used in the study for in vitro modeling, A549 and H1299, do not 
harbor EGFR mutations, but rather RAS and p53 mutations, respectively. These genomic 
discrepancies further support our initial hypothesis that KAT5 behaves differently under 
niche genomic perturbations.  
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 In conclusion, our results show inhibition of KAT5 or potential combination 
therapies with EGFR TKIs could be attractive strategies to treat non-small cell lung 
cancer. The tyrosine phosphorylation of KAT5 by EGFR offers a possible biochemical 
mechanism for the tumorigenic activity of KAT5 as well as another therapeutic option. 
RNA-Sequencing identified numerous oncogenic targets that provide further 
opportunities to elucidate KAT5-dependent tumorigenic pathways. With lung cancer 
contributing to a vast amount of worldwide cancer-related deaths, it is an imperative to 
find new molecular targets to better optimize treatment protocol for patients with this 
disease.   
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